Timothy Hughes

Professor

  • 33340 Citations
  • 75 h-Index
1989 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Public Profile

Professor Timothy Hughes is the Precision Medicine Theme Leader at SAHMRI and Consultant Haematologist in the Division of Haematology at SA Pathology. He is also the Cancer Council Chair in Cancer Research, Chair of the International Chronic Myeloid Leukemia Foundation (iCMLf) and Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).

Professor Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 250 papers that have been cited over 40,000 times. 

In October 2017 Professor Hughes was awarded the GSK Award for Research Excellence 2017 for pioneering the use of tyrosine kinase inhibitors (TKIs).

Education/Academic qualification

PhD, Doctor of Medicine , University of New South Wales

… → 1993

Fellowship of the Royal Australasian College of Physicians

… → 1988

Fellowship of the Royal College of Pathologists of Australia

… → 1988

MB BS (Honours), University of New South Wales

… → 1981

External positions

Consultant Haematologist , SA Pathology

Beat Cancer Professor, University of Adelaide

Chair, International CML Foundation

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL

Tavakoli Shirazi, P., Eadie, L., Heatley, S., Hughes, T., Yeung, D. & White, D., 18 Feb 2020, In : British Journal of Cancer. 122, 4, p. 455-464 10 p.

Research output: Contribution to journalReview article

Asciminib in chronic myeloid leukemia after Abl kinase inhibitor failure

Hughes, T., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y. T., Talpaz, M., Hochhaus, A., Coutre, P. L., Ottmann, O., Heinrich, M. C., Steegmann, J. L., Deininger, M. W. N., Janssen, J. J. W. M., Mahon, F. X., Minami, Y., Yeung, D., Ross, D. & 10 othersTallman, M. S., Park, J. H., Druker, B. J., Hynds, D., Duan, Y., Meille, C., Hourcade-Potelleret, F., Vanasse, K. G., Lang, F. & Kim, D. W., 12 Dec 2019, In : New England Journal of Medicine. 381, 24, p. 2315-2326 12 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)
1 Citation (Scopus)

Early Management of CML

Shanmuganathan, N. & Hughes, T., 1 Dec 2019, In : Current Hematologic Malignancy Reports. 14, 6, p. 480-491 12 p.

Research output: Contribution to journalReview article

1 Citation (Scopus)

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib

Kok, C., Yeung, D., Lu, L., Watkins, D. B., Gray, T., Dang, Y., Saunders, V., Reynolds, J., White, D. & Hughes, T., 28 May 2019, In : Blood Advances. 3, 10, p. 1610-1621 12 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)